排序方式: 共有10条查询结果,搜索用时 31 毫秒
1
1.
2.
3.
4.
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease 总被引:24,自引:0,他引:24
Schreiber S Rutgeerts P Fedorak RN Khaliq-Kareemi M Kamm MA Boivin M Bernstein CN Staun M Thomsen OØ Innes A;CDP Crohn's Disease Study Group 《Gastroenterology》2005,129(3):807-818
BACKGROUND & AIMS: To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti-tumor necrosis factor, CDP870) in Crohn's disease. METHODS: In a placebo-controlled, phase II study, 292 patients with moderate to severe Crohn's disease received subcutaneous certolizumab 100, 200, or 400 mg or placebo at weeks 0, 4, and 8. The primary end point was the percentage of patients with a clinical response at week 12 (a Crohn's Disease Activity Index decrease of > or = 100 points or remission [Crohn's Disease Activity Index < or = 150 points]) in the intent-to-treat population. RESULTS: All certolizumab doses produced significant clinical benefit over placebo at week 2 (placebo, 15.1%; certolizumab 100 mg, 29.7% [P = .033]; 200 mg, 30.6% [P = .026]; 400 mg, 33.3% [P = .010]). At all time points, the clinical response rates were highest for certolizumab 400 mg, greatest at week 10 (certolizumab 400 mg, 52.8%; placebo, 30.1%; P = .006) but not significant at week 12 (certolizumab 400 mg, 44.4%; placebo, 35.6%; P = .278). Patients with baseline C-reactive protein levels of 10 mg/L or greater (n = 119) showed clearer separation between active treatment and placebo (week 12 clinical response: certolizumab 400 mg, 53.1%; placebo, 17.9%; P = .005; post hoc analysis) owing to a lower placebo response rate than patients with C-reactive protein levels of less than 10 mg/L. Adverse events were similar among groups. CONCLUSIONS: Certolizumab 400 mg may be effective and is well tolerated in patients with active Crohn's disease. High placebo response rates in the large patient subgroup with low C-reactive protein levels may have obscured statistical separation between certolizumab and placebo. Ongoing phase III trials are necessary to establish the clinical efficacy of certolizumab. 相似文献
5.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial 总被引:32,自引:0,他引:32
Sandborn WJ Feagan BG Hanauer SB Present DH Sutherland LR Kamm MA Wolf DC Baker JP Hawkey C Archambault A Bernstein CN Novak C Heath PK Targan SR;CDP Crohn's Disease Study Group 《Gastroenterology》2001,120(6):1330-1338
BACKGROUND & AIMS: We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the treatment of active Crohn's disease. METHODS: One hundred sixty-nine patients with moderate-to-severe Crohn's disease were enrolled in a 24-week placebo-controlled trial. Patients were initially randomized to a single dose of 10 or 20 mg/kg CDP571 or placebo to assess dose response. Patients were then retreated with 10 mg/kg CDP571 or placebo every 8 or 12 weeks to assess subsequent dosing intervals. The primary endpoint was clinical response at week 2, defined as a decrease in the Crohn's Disease Activity Index score > or = 70 points. RESULTS: At week 2, clinical response occurred in 45% of CDP571-treated patients compared with 27% of patients in the placebo group (P = 0.023). Patients appeared to benefit from retreatment with CDP571 over 24 weeks, but not all of the results for secondary endpoints were statistically significant. The frequency of severe or serious adverse events was similar among all groups. CONCLUSIONS: CDP571 at an initial dose of 10 or 20 mg/kg is safe and effective for treatment of patients with moderate-to-severe Crohn's disease. Preliminary evidence suggests that retreatment with 10 mg/kg CDP571 at dose intervals of 8 or 12 weeks may also be beneficial, but additional studies are needed. 相似文献
6.
7.
This paper presents an evaluation methodology for assessing information systems in office practice. The premise is that a meaningful evaluation of information systems in office practice should be a threefold process: First, assess the internal performance of the information system; second, analyze the communication between the users and the information system; and third, evaluate how well practice managers utilize information prepared by the system in managing the practice. The paper approaches the topic from a systems perspective and develops the research method through the presentation of criteria for each of the three evaluation components. 相似文献
8.
This study examines and presents outcome analyses of characteristics of treatment completers versus treatment noncompleters in a Targeted Capacity Expansion (TCE) and HIV/AIDS Education Program for adolescents with substance use disorders, using a two-group nonrandomized design. The treatment completion rate was 47%, exceeding the national average of 40% for outpatient clients. These results suggest the importance of utilizing comprehensive assessments, providing linkages to assertive continuing care, and developing curricula to meet cultural, developmental, and gender-specific needs of adolescent clients. The TCE and HIV/AIDS Education Program appears to be an effective program for reducing and eliminating substance abuse among adolescents. 相似文献
9.
Rutgeerts P Schreiber S Feagan B Keininger DL O'Neil L Fedorak RN;CDP Crohn's Disease Study Group 《International journal of colorectal disease》2008,23(3):289-296
Background and aims Certolizumab pegol, a polyethylene glycolated Fc-free Fab’ was efficacious and well tolerated in patients with moderate-to-severe
Crohn’s disease in a previously reported randomized, placebo-controlled study. In this paper, we report the effect of certolizumab
pegol on health-related quality of life (HRQoL).
Materials and methods Patients with moderate-to-severe active Crohn’s disease (n = 292) received subcutaneous certolizumab pegol 100, 200, or 400 mg or placebo at weeks 0, 4, and 8. A post hoc analysis of
the intent-to-treat population (290 patients with HRQoL data) assessed HRQoL by evaluating patients’ responses to the self-administered
inflammatory bowel disease questionnaire (IBDQ) at baseline and weeks 2, 4, 6, 8, 10, and 12.
Results Patients receiving certolizumab pegol 400 mg at weeks 0, 4, and 8 demonstrated, via their IBDQ total score, significantly
(P ≤ 0.05) greater improvement in HRQoL from baseline to week 12 and at all other time points compared with placebo. Moreover,
HRQoL improved over time in all certolizumab pegol groups, irrespective of baseline C-reactive protein levels. Emotional well-being
(IBDQ Emotional Function domain) improved throughout the study for patients receiving certolizumab pegol 400 mg. This improvement
was significantly (P ≤ 0.05) greater than for patients receiving placebo at all time points. In addition, systemic symptoms (IBDQ Systemic Symptoms
domain) improved significantly more in patients receiving certolizumab pegol 400 mg than in those receiving placebo at weeks
4, 8, 10, and 12 (P ≤ 0.05) and approached statistical significance at week 2 (P = 0.054).
Conclusion This analysis suggests that certolizumab pegol 400 mg improves HRQoL in patients with moderate-to-severe Crohn’s disease. 相似文献
10.
1